« Back
Home /
Ursodeoxycholic acid (Standard)

Ursodeoxycholic acid (Standard)

Item no.	HY-13771R-100mg
Manufacturer	MedChem Express
CASRN	128-13-2
Amount	100 mg
Quantity options	1 ea 100 mg 250 mg 25 mg 50 mg
Category	Reagents & Chemicals Standards, Ladders & Markers Other Standards
Type	Standard
Specific against	other
Citations	[1]Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7.\|[2]Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14.\|[3]Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56(4):1300-10.\|[4]Brevini T, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022 Dec 5.\|[5]Winston JA, et al. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16(2):e0246161. Published 2021 Feb 18.
Smiles	C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
ECLASS 10.1	42021590
ECLASS 11.0	42021590
UNSPSC	12352202
Alias	Ursodeoxycholate (Standard),Ursodiol (Standard),UDCA (Standard)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference Standards
Manufacturer - Targets	Angiotensin-converting Enzyme (ACE); Endogenous Metabolite; FXR; G protein-coupled Bile Acid Receptor 1; Reference Standards
Shipping Temperature	Room temperature
Molecular Weight	392.57
Product Description	Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active[1][2][3][4].
Manufacturer - Research Area	Cancer; Infection; Metabolic Disease
Manufacturer - Pathway	GPCR/G Protein; Metabolic Enzyme/Protease; Others

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question